

30 October 2020

NEUROSCIENTIFIC BIOPHARMACEUTICALS LIMITED ANNUAL GENERAL MEETING – NOTICE AND PROXY FORM

Dear Shareholder

Notice is hereby given that the Annual General Meeting of Shareholders of NeuroScientific Biopharmaceuticals Limited (ASX:NSB) (ACN 102 832 995) ("Company") will be held virtually via webinar on Monday, 7 December 2020 at 11.00am (WST) (Meeting).

Given the significant health concerns attributed to the COVID-19 pandemic, in addition to guidelines and restrictions issued by Australian state and federal governments, the Company considers that it is appropriate to hold the Annual General Meeting as a virtual meeting accessible online, in a manner that is consistent with the temporary modifications to the Corporations Act 2001 (Cth) introduced by the Commonwealth Treasurer.

Shareholders will be able to attend and participate in the Meeting via live Zoom audiocast by registering at:

https://us02web.zoom.us/webinar/register/WN_rkZSjb5dSBihG6XyRYmWnw

Further instructions are set out in the Notice of Meeting (NoM).

In accordance with section 5(1)(f) of the Corporations (Coronavirus Economic Response) Determination (No. 1) 2020 made by the Commonwealth Treasurer on 5 May 2020, the Notice is being made available to Shareholders electronically and can be viewed and downloaded online at the following link: https://neuroscientific.com/investors/

If you have not elected to receive notices by email, you will receive this letter by mail with a copy of your personalised proxy form enclosed for your convenience. Please complete and return the attached proxy form to the Company's share registry, Automic Group Pty Ltd by:

post to: Automic

GPO Box 5193 Sydney NSW 2001

or

in person to: Automic

Level 5, 126 Phillip Street Sydney NSW 2000

OI

email to: meetings@automicgroup.com.au

Proxy votes may also be lodged online at https://investor.automic.com.au/#/loginsah.

Your proxy voting instruction must be received by 11.00am (WST) on Saturday, 5 December 2020, being not less than 48 hours before the commencement of the Meeting. Any proxy voting instructions received after that time will not be valid for the Meeting.

Matthew Liddelow CEO and Managing Director ml@neuroscientific.com +61 8 6382 1805 Brian Leedman Non-executive Chairman bl@neuroscientific.com +61 412 281 780